DeCure for Autoimmune disorder of the nervous system
DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for autoimmune disorder of the nervous system — screening already-approved drugs against its 30-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAutoimmune disorder of the nervous system maps to a 30-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for autoimmune disorder of the nervous system is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
potassium voltage-gated channel subfamily C member 1 (KCNC1) — KCNC1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QUD · 2.5 Å · ligand (5R)-5-ethyl-3-(6-spiro[2H-1-benzofuran-3,1'-cyclopropane]-4-yloxypyridin-3-yl)imidazolidine-2,4-dione (WY0). Experimental structure, not a prediction.
What the evidence adds up to
Autoimmune neurologic disorders encompass a broad category of diseases in which the immune system attacks the central, peripheral, or autonomic nervous systems. Over the past 20 years, more than 50 antibodies have been identified and associated with these disorders. The therapeutic approach has largely continued to rely on expert opinion, case series, and case reports. The US Food and Drug Administration has approved biologic agents to treat neuromyelitis optica spectrum disorder and myasthenia gravis, and ongoing clinical trials are underway for the treatment of autoimmune encephalitis. The urgency to intervene to prevent permanent damage to the nervous system often conflicts with diagnostic uncertainty.
Some neurological diseases may reflect a dysfunction of the immune system in which highly specific autoantibodies are generated that bind neuronal glutamate receptors and directly affect their function in normal neurotransmission. An ever-increasing collection of neurological human diseases are becoming appreciated as encompassing a strong immunological component, including Parkinson's disease, Alzheimer's, stroke, narcolepsy, schizophrenia and psychosis. In most cases, the specific roles played by the immune response in these disease processes is largely uncharted and will require considerable investigation.
Autoimmune disorders of the nervous system are generally diagnosed at a younger age than other acquired disorders of the nervous system, such as infections or vascular injuries, though all age groups can be affected. Patients commonly present with progressive neurologic dysfunction and some combination of laboratory and radiographic evidence of central nervous system inflammation. The main aim of current investigation is to understand the mechanisms by which the immune system mistakenly attacks components of the nervous system, and to identify the specific auto-antibodies involved, the affected neural pathways, and potential treatment strategies.
What is still missing is robust evidence from clinical trials to inform new therapeutics, rather than reliance on expert opinion and case series. The specific roles of immune responses in most of these disease processes remain largely uncharted. A framework that focuses on early interventions rather than precise diagnosis has been proposed, but the diagnostic uncertainty that conflicts with the urgency to intervene has not been resolved. Patient stratification by specific auto-antibody profiles and disease mechanisms remains an aspirational goal rather than a clinical reality.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Immunology · 2018 · 20 citations · open access
Neuroimmunology and neuroinflammation in autoimmune, neurodegenerative and psychiatric disease
AbstractAn ever-increasing collection of neurological human diseases are becoming appreciated as encompassing a strong immunological component in pathogenesis or regulation. This derives to a large extent from genome-wide association studies that have highlighted association with immune system genes, including those in the HLA and KIR regions. Along with the genomic findings have come insights from immune phenotyping and assays for autoimmunity. This is a group of disease processes that includes Parkinson's disease, Alzheimer's, stroke, narcolepsy, schizophrenia and psychosis. In most cases, these are diseases in which we assume that differential regulation of central nervous system inflammation may impact symptoms and severity. The specific roles played by the immune response in these disease processes is largely uncharted and will require considerable investigation.
Autoimmunity to Glutamate Receptors in Rasmussen's Encephalitis: A Rare Finding or The Tip of an Iceberg?
AbstractNeurological disorders demonstrate remarkable specificity in afflicting precise brain regions. They are most frequently sporadic in origin and they are devastating because of the progressive impairment of cognitive and/or motor functions. Our studies have found that some neurological diseases may actually reflect a dysfunction of the immune system in which highly specific autoantibodies are generated that bind neuronal glutamate receptors and directly affect their function in normal neurotransmission. Understanding at the molecular level how the immune system participates in neurological disease will ultimately lead to more effective therapeutic approaches to some of these disorders with presently unknown etiology. NEURO SCIENTIST 4:373-379, 1998
CONTINUUM Lifelong Learning in Neurology · 2024 · 5 citations
Therapeutic Approach to Autoimmune Neurologic Disorders
AbstractOBJECTIVE: Autoimmune neurologic disorders encompass a broad category of diseases characterized by immune system attack of the central, peripheral, or autonomic nervous systems. This article provides information on both acute and maintenance immunotherapy used to treat autoimmune neurologic disorders as well as a review of symptomatic management and special considerations when caring for patients with these diseases. LATEST DEVELOPMENTS: Over the past 20 years, more than 50 antibodies have been identified and associated with autoimmune neurologic disorders. Although advances in diagnostic testing have allowed for more rapid diagnosis, the therapeutic approach to these disorders has largely continued to rely on expert opinion, case series, and case reports. With US Food and Drug Administration (FDA) approval of biologic agents to treat neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis as well as ongoing clinical trials for the treatment of autoimmune encephalitis, the landscape of immunotherapy options continues to expand. Consideration of the unique pathogenesis of individual autoimmune neurologic disorders as well as the mechanism of action of the diverse range of treatment options can help guide treatment decisions today while evidence from clinical trials informs new therapeutics in the future. ESSENTIAL POINTS: Recognizing patients who have a clinical history and examination findings concerning for autoimmune neurologic disorders and conducting a thorough and directed imaging and laboratory evaluation aimed at ruling out mimics, identifying specific autoimmune syndromes, and screening for factors that may have an impact on immunotherapy choices early in the clinical course are essential to providing optimal care for these patients. Providers must consider immunotherapy, symptomatic treatment, and a multidisciplinary approach that addresses each patient's unique needs when treating patients with autoimmune neurologic disorders.
AbstractAutoimmune disease affecting the central nervous system is a common cause for admission to the neurointensive care unit. Although well-described clinical syndromes exist, patients more commonly present with progressive neurologic dysfunction and some combination of laboratory and radiographic evidence of central nervous system inflammation. The urgency to intervene to prevent permanent damage to the nervous system often conflicts with diagnostic uncertainty. This chapter outlines some of the basic diagnostic and therapeutic principles of autoimmune diseases of the central nervous system. The chapter characterizes disorders not as a list of individual disease entities but rather as clusters of syndromes based on common underlying mechanisms of immune dysfunction. This approach focuses on early interventions rather than precise diagnosis. As our understanding of the immune system continues to grow, this framework will allow for a more sophisticated approach to the management of patients with these complex, often devastating but frequently reversible, neurologic illnesses.
International Journal of Pharmaceutical Research and Applications · 2025 · 0 citations · open access
An Integrative Review on Autoimmune Neurological Disorder
AbstractAutoimmune diseases are conditions in which our immune system mistakenly damages healthy cells in the body and it occurs when the body's immune system mistakenly attacks and damages its own tissues, instead of fighting off foreign invaders like bacteria or viruses. This happens because the immune system loses the ability to distinguish between healthy cells and those that are foreign, leading to inflammation and damage. In the past few decades, autoimmune and non-infectious inflammatory disorders of the nervous system have become increasingly recognized as major sources of disease and disability. Autoimmune disorders of the nervous system are generally diagnosed at a younger age than other acquired disorders of the nervous system, such as infections or vascular injuries. However, all age groups can be affected. The main aim of this investigation is understand the mechanisms by which the immune system mistakenly attacks components of the nervous system, leading to neurological disorders. By exploring the specific auto - antibodies involved, the affected neural pathways, and potential treatment strategies to shed light on the causes, pathology, and management of neurological conditions arising from autoimmune responses within the central and peripheral nervous systems. By identifying the specific antibodies that target components of the nervous system in different autoimmune neurological diseases, can help with diagnosis and treatment development. By understanding the disease mechanism to know how these auto antibodies interact with neural tissues and disrupt normal nervous system function is crucial for developing targeted therapies
Journal of the Turkish Epilepsi Society · 2015 · 0 citations · open access
Autoimmune Diseases Associated with Epilepsy
AbstractInvolvement of the central nervous system (CNS) during the course of systemic autoimmune diseases is not rare. Connective tissue disorders such as systemic lupus erythematosus (SLE), rheumatoid arthritis, Behet's disease; granulomatous disorders such as sarcoidosis, granulomatous angitis; autoimmune bowel disorders such as inflammatory bowel and Celiac diseases; thyroid disorders such as Hashimoto and Graves diseases are best examples of the autoimmune diseases in this category. Epileptic seizures may be observed in patients with and without any obvious lesions in these disorders. In this review, we will summarize patterns of neurological involvement in systemic autoimmune diseases associated with epilepsy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
